Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Palo (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Palo (Details)
$ in Thousands
12 Months Ended
Sep. 26, 2019
USD ($)
item
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs   $ 14,650 $ 8,000  
Long-term royalty and commercial payment receivables   57,952 63,683 $ 69,075
Short-term royalty and commercial payment receivables   14,215 $ 2,366  
Palo | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 6      
Payments of consideration under RPAs, AAAs and CPPAs $ 10,000      
Long-term royalty and commercial payment receivables $ 10,000      
Amount of allowance for credit losses   $ 0